SGO1 and hepatocellular carcinoma: Current studies have identified that SGOL1 is upregulated and serves as a prognostic and therapy-related biomarker in various cancers, such as breast cancer, hematological malignancies, lung cancer, glioma, colon cancer, and hepatocellular carcinoma [17–20].